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Supplementary Table e-1. Demographic and clinical characteristics of the London and Oxford 
cohorts separately and combined.  
n (%) London-ALS 
(n=103) 
Oxford-ALS 
(n=64) 
Combined-
ALS (n=167) 
London-
CTRL*# 
(n=42) 
Oxford-
CTRL* 
(n=36) 
Combined- 
CTRL*# 
(n=78) 
Gender 
 
Male 66 (64%) 45 (70%) 112 (67%) 15 (35.7%) 15 (41.7%) 30 (38.5%) 
Female 37 (36%) 19 (30 %) 56 (33%) 27 (64.3%) 21 (58.3%) 48 (61.5%) 
Age of baseline 
sampling (years) 
 
<60 32 (31%) 27 (42%) 59 (35.3%) 21 (50%) 24 (66.7%) 45 (57.7%) 
60-69 41 (40%) 25 (39%) 66 (39%) 11 (26%) 10 (27.8%) 21 (26.9%) 
70-79 20 (19.4%) 10 (16%) 30 (17.9%) 7 (16.7%) 2 (5.5%) 9 (11.5%) 
≥80 10 (9.6%) 2 (3%) 13 (7.8%) 1 (2.3%) 0 1 (1.3%) 
Age of onset 
(years) 
<60 36 (35%) 31 (48.4%) 67 (40%)    
60-69 42 (40.7%) 25 (39%) 67(40%) 
70-79 18 (17.5%) 7 (11%) 25 (15%) 
≥80 7 (6.8%) 1 (1.6%) 9 (5%) 
Site of symptom 
onset 
Limb 81 (78.6%) 51 (79.7%) 132 (79%) 
Bulbar 20 (19.4%) 13 (20.3%) 33 (19.8%) 
Both 2 (2%) 0 2 (1.2%) 
Diagnosis Definite 19 (18.5%) 20 (31%) 39 (23%) 
Probable 47 (45.6%) 21 (33%) 69 (41%) 
Possible  27 (26.2%) 23 (36%) 50 (30%) 
Laboratory-
supported  
10 (9.7%) 0 10 (6%) 
Diagnostic 
latency (months) 
 
<12 55 (53.4%) n/a n/a 
12-23 29 (28.2%) n/a n/a 
24-35 10 (9.7%) n/a n/a 
≥36 9 (8.7%) n/a n/a 
Duration to 
Baseline 
sampling 
(months) 
 
<12 24 (23.3%) 9 (14%) 33 (19%) 
12-23 32 (31.1%) 20 (31.3%) 52 (31%) 
24-35 23 (22.3%) 14 (21.9%) 38 (23%) 
≥36+ 24 (23.3%) 21 (32.8%) 45 (27%) 
Ethnicity Non-Caucasian 6 (5.8%) 0 6 (3.6%) 
C9orf72* Positive case 3 (2.91%) 2 (3.1%) 5 (2.99%) 
ALSFRS_R* 47-40 37 (35.9%) 12 (18.8%) 49 (29.3%) 
score at baseline 39-26 52 (50.5%) 50 (78.1%) 102 (61.1%) 
<=25 14 (13.6%) 2 (3.1%) 16 (9.6%) 
Progression rate 
at Baseline 
(PRB) 
 
Fast: >1.0 22 (21.4%) 11 (17.2%) 33 (19.8%) 
Intermediate: 
0.5-1.0 
30 (29.1%) 17 (26.6%) 47 (28.1%) 
Slow: <0.5 51 (49.5%) 36 (56.2%) 87 (52.1%) 
Progression rate 
at the last visit 
(PRL) 
Fast: >1.0 31 (30.1%) 15 (23.4%) 46 (27.5%) 
Intermediate: 
0.5-1.0 
29 (28.2%) 18 (28.2%) 47 (28.2%) 
Slow: <0.5 43 (41.7%) 31 (48.4%) 74 (44.3%) 
Riluzole 
Treatment 
With 74 (71.8%) 30 (46.9%) 104 (62.3%) 
without 29 (28.2%) 34 (53.1%) 63 (37.7%) 
*: CTRL: controls; C9orf72: chromosome 9 open reading frame 72; ALSFRS_R: ALS 
functional rating scale-revised; #: date of birth from two controls was not available. 
Information for diagnostic latency was not available in Oxford cohort. 
